Ruth Pettengell

17.3k total citations · 2 hit papers
199 papers, 7.8k citations indexed

About

Ruth Pettengell is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Ruth Pettengell has authored 199 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 94 papers in Pathology and Forensic Medicine and 49 papers in Hematology. Recurrent topics in Ruth Pettengell's work include Lymphoma Diagnosis and Treatment (92 papers), Neutropenia and Cancer Infections (46 papers) and Hematopoietic Stem Cell Transplantation (35 papers). Ruth Pettengell is often cited by papers focused on Lymphoma Diagnosis and Treatment (92 papers), Neutropenia and Cancer Infections (46 papers) and Hematopoietic Stem Cell Transplantation (35 papers). Ruth Pettengell collaborates with scholars based in United Kingdom, United States and Germany. Ruth Pettengell's co-authors include Gary H. Lyman, John Radford, Jan Walewski, D. Crowther, Matti Aapro, Vivianne C. G. Tjan‐Heijnen, David Cameron, Julia Bohlius, Nora Kearney and Damien C. Weber and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Ruth Pettengell

192 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

2010 777 citations Ruth Pettengell, Jan Walewski et al. profile →
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

2015 407 citations John Radford, Tim Illidge et al. profile →

Peers

Countries citing papers authored by Ruth Pettengell

Since Specialization

Citations

This map shows the geographic impact of Ruth Pettengell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Pettengell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Pettengell more than expected).

Fields of papers citing papers by Ruth Pettengell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Pettengell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Pettengell. The network helps show where Ruth Pettengell may publish in the future.

Co-authorship network of co-authors of Ruth Pettengell

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Pettengell. A scholar is included among the top collaborators of Ruth Pettengell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Pettengell. Ruth Pettengell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial 2024 ·Blood ·John Radford, (unknown), (unknown), Ruth Pettengell, Peter Johnson, Peter Hoskin, Tim Illidge, Nicholas Counsell	0
2	Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline 2021 ·British Journal of Haematology ·Christopher P. Fox, Matthew J. Ahearne, Ruth Pettengell, Claire Dearden, Dima El‐Sharkawi, Shireen Kassam, Lucy Cook, Kate Cwynarski, Tim Illidge, Graham P. Collins	17
3	Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial 2021 ·Bone Marrow Transplantation ·Ruth Pettengell, (unknown), Ariane Boumendil, Roderick J. Johnson, Bernd Metzner, Alejandro Martı́n, Joanna Romejko‐Jarosińska, Isabelle Bence‐Bruckler, (unknown), Carsten Utoft Niemann, Stephen Robinson, Eva Kimby, Norbert Schmitz, Peter Dreger, A. H. Goldstone, Silvia Montoto	7
4	Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial 2020 ·SHILAP Revista de lepidopterología ·Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrans, (unknown), Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton‐Hadley, David C. Linch, Andrew McMillan	6
5	Construction of the secondary care administrative records frailty (SCARF) index and validation on older women with operable invasive breast cancer in England and Wales: a cohort study 2020 ·BMJ Open ·(unknown), Melissa Gannon, David Dodwell, Kieran Horgan, Karen Clements, Francisco J. Medina, Carmen Tsang, Thompson Robinson, (unknown), Ruth Pettengell, David Cromwell	31
6	Relaxation versus exercise for improved quality of life in lymphoma survivors—a randomised controlled trial 2020 ·Journal of Cancer Survivorship ·(unknown), Ruth Pettengell, Hannah Moir, Anan Younis	17
7	Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy 2017 ·Immunity Inflammation and Disease ·(unknown), (unknown), (unknown), Ruth Pettengell	33
8	Enhanced formation of giant cells in common variable immunodeficiency: Relation to granulomatous disease 2016 ·Clinical Immunology ·(unknown), (unknown), Ruth Pettengell, David Webster	8
9	The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma 2016 ·Clinical Therapeutics ·N. Muszbek, Ananth Kadambi, Tereza Lanitis, Anthony J. Hatswell, Dilip Patel, Lixia Wang, Jack W. Singer, Ruth Pettengell	9
10	Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation 2013 ·Journal of Clinical Oncology ·Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, Graeme Smith, W. N. Patton, Bernd Metzner, Dolores Caballero, Hervé Tilly, Jan Walewski, Isabelle Bence‐Bruckler, Bik To, Christian H. Geisler, Rik Schots, Eva Kimby, Christian Taverna, Tomáš Kozák, Peter Dreger, Ruzena Uddin, Carmen Ruiz de Elvira, Anthony H. Goldstone	77
11	Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 2009 ·Journal of Clinical Oncology ·Peter Hoskin, Lisa Lowry, Alan Horwich, Andrew Jack, (unknown), Barry W. Hancock, Paul Smith, Wendi Qian, (unknown), Bilyana Popova, Andrew R. Pettitt, David Cunningham, Ruth Pettengell, John Sweetenham, David C. Linch, Peter Johnson	124
12	Treatment response predictor using 31P MRS for CHOP and R-CHOP therapy in diffuse large B-cell lymphoma 2008 ·Cancer Research ·Fernando Arias‐Mendoza, Geoffrey S. Payne, Kristen L. Zakian, Marion Stubbs, (unknown), Adam J. Schwarz, Amita Shukla‐Dave, Franklyn A. Howe, N. Maisey, David Cunningham, Harish Poptani, Mitchell R. Smith, (unknown), Ruth Pettengell, Martin O. Leach, Jason A. Koutcher, John R. Griffiths, Arend Heerschap, Jerry D. Glickson, Truman R. Brown	2
13	Antagonism of HOX/PBX Dimer Formation Blocks the In vivo Proliferation of Melanoma 2007 ·Cancer Research ·Richard Morgan, (unknown), (unknown), Jastinder Sohal, Ruth Pettengell, Hardev Pandha	83
14	Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: Evidence of a therapeutically relevant graft-versus-lymphoma effect. 2003 ·UCL Discovery (University College London) ·K Peggs, (unknown), (unknown), Premini Mahendra, D W Milligan, (unknown), Ann Hunter, Ruth Pettengell, (unknown), G Hale, Herman Waldmann, Emma Morris, AH Goldstone, DC Linch, Stephen Mackinnon	5
15	Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect. 2001 ·UCL Discovery (University College London) ·PD Kottaridis, DW Milligan, (unknown), Charles Craddock, (unknown), K Peggs, (unknown), Johanne Geary, (unknown), Premini Mahendra, (unknown), A M Hunter, Ruth Pettengell, G Hale, Herman Waldmann, DC Linch, AH Goldstone, Stephen Mackinnon	4
16	Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines 2000 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·(unknown), Ruth Pettengell, Ian Clarke, Gernot Stuhler, (unknown), Peter Walden, Angus Dalgleish	76
17	A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy. 1999 ·Blood ·PD Kottaridis, (unknown), D W Milligan, Sakti Chakrabarti, Stephen Robinson, (unknown), Ruth Pettengell, Judith Marsh, Premini Mahendra, Stephen Schey, (unknown), Casey Williams, G Hale, Herman Waldmann, D C Linch, Stephen Devereux, A. H. Goldstone, Stephen Mackinnon	6
18	Identification of emerging CD34 progenitor subsets. 1998 ·UCL Discovery (University College London) ·Colin McGuckin, Daniel J. Pearce, Arnold Pizzey, (unknown), (unknown), Ruth Pettengell	1
19	Expanding the role of blood progenitor cells 1995 ·Annals of Oncology ·Ruth Pettengell	0
20	Peripheral blood progenitor cells PBPC for haemopoietic rescue for poor prognosis high grade NHL 1992 ·Research Explorer (The University of Manchester) ·Ruth Pettengell, John Radford, (unknown), D.P. Deakin, NG Testa, D. Crowther	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact